ACADIA Pharmaceuticals Inc. (ACAD) traded negative at $34.57. On an intraday basis, the price dropped -0.02 points or -0.07%. The composite uptick value was $21.17 million while the combined downtick value was $16.42. The net money flow was $4.75 million while the up/down ratio was not very comforting at 1.29. The shares on a weekly note has seen a change in share price of 8.25%.According to the trading data, the shares saw a block trade with $3.67 million in upticks and $1.37 million in downticks. The up/down ratio for the block was calculated to be 2.69. The net money flow for the block trade was 2.31.Block trades are executed by Investment Banking firms or Wealth Managers shifting positions or Day traders taking advantage of trading signals.
Shares of ACADIA Pharmaceuticals Inc. rose by 10.79% in the last five trading days and 19.59% for the last 4 weeks. ACADIA Pharmaceuticals Inc. is up 47.96% in the last 3-month period. Year-to-Date the stock performance stands at 19.59%. ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) witnessed a decline in the market cap on Wednesday as its shares dropped 0.29% or 0.1 points. After the session commenced at $34.65, the stock reached the higher end at $35.38 while it hit a low of $34.06. With the volume soaring to 2,724,386 shares, the last trade was called at $34.49. The company has a 52-week high of $42.49. The company has a market cap of $4,177 million and there are 121,113,846 shares in outstanding. The 52-week low of the share price is $16.64.
Company has reported several Insider transactions to the SEC, on Dec 29, 2016, Glenn Baity (EVP AND GC) sold 9,800 shares at 30.46 per share price.On Feb 19, 2015, Uli Hacksell (CEO) sold 30,000 shares at 34.30 per share price.
ACADIA Pharmaceuticals Last issued its quarterly earnings results on Nov 7, 2016. The company reported $-0.61 EPS for the quarter, missing the analyst consensus estimate by $ -0.04. Analyst had a consensus of $-0.57. The company had revenue of $5.30 million for the quarter, compared to analysts expectations of $2.62 million. The companys revenue was up 13489.7% compared to the same quarter last year. During the same quarter in the previous year, the company posted $-0.39 EPS.
Several Stock Research Financial Advisors from Investment Banking firms have advised their client and investors on the stock.ACADIA Pharmaceuticals was Initiated by Goldman to Neutral on Nov 11, 2016. ACADIA Pharmaceuticals was Upgraded by BofA/Merrill to Buy on Nov 8, 2016.
Acadia Pharmaceuticals is a biopharmaceutical company focused on the discovery, development and commercialization of small molecule drugs for the treatment of central nervous system disorders. Their three clinical programs are ACP-103 for treatment-induced dysfunction in Parkinsons disease, and ACP-104 and ACP-103, both for the treatment of schizophrenia.